J&J | JNJ - Cash And Equivalent


J&J reported $21.69B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Abbott USD 6.8B 1.72B Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Boston Scientific USD 1.45B 512M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
CONMED USD 40.82M 1.89M Dec/2025
Cooper Companies USD 124.9M 14.3M Dec/2025
Dexcom USD 1.12B 200.5M Mar/2026
Edwards Lifesciences USD 2.4B 538M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Globus Medical USD 560.95M 34.79M Mar/2026
Insulet USD 480.4M 235.7M Mar/2026
Integra LifeSciences USD 236.81M 1.76M Mar/2026
Intuitive Surgical USD 8.63B 646.3M Jun/2026
J&J USD 21.69B 1.98B Mar/2026
Medtronic USD 1.15B 135M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Merit Medical Systems USD 488.08M 41.68M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Stryker USD 2.88B 1.13B Mar/2026
Tandem Diabetes Care USD 179.32M 88.69M Mar/2026
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Zimmer Biomet Holdings USD 424.2M 167.7M Mar/2026
Zoetis USD 1.94B 369M Mar/2026